This study examines the challenges in ensuring patients with NTRK alterations receive appropriate targeted treatments despite the effectiveness of available drugs, and emphasizes the need for improved strategies. 

Click the link below to access the abstract 

Read the abstract

NTRK positivity and conversion to appropriate personalized treatment.

Bethany Michelle Slifko, Howard L. McLeod, Wendy Moore, Inês Abrunhosa Amaral, Susanne Munksted

Over the past 6 months, Diaceutics have delivered a series of digital  activities focused on the new and emerging perspectives on the classification of HER2 in breast cancer. 

Our aim is to raise awareness of the new perspectives emerging on HER2 testing and expression, particularly in relation to recognizing low levels of HER2 in breast cancer patients. 

Catch-up on the activities in this series to: 

 about the importance of recognizing HER2 low and HER2 negative patients and how this can be implemented in your lab

 to Key Opinion Leader, Professor Dr Abeer Shaaban, discuss her perspective on HER2 expression during the Lab Talk,

 A new perspective on HER2 testing- Evolving the lab practices to match clinical advances

the HER2 Report Checklist from the series and share with colleagues or print and display in your labs for ease of reference 

, we highlighted that up to 60% of breast cancers classed as HER2 negative have detectable levels of HER2 expression

. This has created a need for a consistent assessment standard that recognizes HER2 biomarker expression as a spectrum of negative, low and positive, encouraging labs to re-think what they know about determining HER2 expression and how this can impact patients.  

 with Professor Dr Abeer Shaaban MSc, PhD, FRCPath. During this session, Prof. Dr Shaaban discussed the clinical utility of HER2 testing, HER2 scoring and the spectrum of expression and the technical factors to be considered, including analytical and pre-analytical. 

Register interest 

1.  Schettini  F, et  al.  NPJ  Breast  Cancer.  2021;7:1-13.

This  content  is  organized and funded  by  AstraZeneca. This content  is  intended  for  healthcare  professionals  only. Z4-62779. DOP July 2024.

Diese digitalen Dialoge unterstreichen die Bedeutung von KIT D816V für die Diagnose und therapeutische Entscheidungsfindung, sowie die Notwendigkeit einer optimalen Patientenidentifizierung.

Informieren Sie sich über die Aktivitäten in dieser Reihe und:

Sie mehr über die Bedeutung von KIT D816V, den Weg eines SM-Patienten vom Verdacht bis zur Diagnose und Faktoren, die zu Fehldiagnosen führen können

 Sie von unserem Experten Prof. Dr. med. Hans Michael Kvasnicka, mehr über KIT D816V und die positiven Auswirkungen, die ein effiziente Diagnose auf Patienten haben kann

Sie das DiagnosetoolKIT für Systemische Mastozytose, die FAQs und die Folien des Lab Talks herunter, die Sie gerne auch an Kollegen weitergeben oder für Ihr Labor ausdrucken und als schnell zugängliche Informationsquelle aushängen können.

Unser erster Lab Alert konzentrierte sich auf die fortgeschrittene Systemische Mastozytose (AdvSM) und wir haben dabei hervorgehoben, dass 90-95 % der AdvSM Patienten KIT D816V-positiv

 sind und welche entscheidende Rolle diese Mutation sowohl bei der diagnostischen Abklärung bei SM-Verdachtspatienten als auch bei Behandlungsentscheidungen spielt. 

, um den vollständigen Artikel zu lesen und das DiagnosetoolKIT für systemische Mastozytose herunterzuladen.

Anschließend fand ein Lab Talk mit Prof. Dr. med. Hans Michael Kvasnicka statt, in dem er den Weg des SM-Patienten bis zur Diagnose, die klinische Bedeutung von KIT D816V bei Patienten mit systemischer Mastozytose, einschließlich fortgeschrittener SM (AdvSM) und indolenter SM (ISM) beschrieb. Weiterhin wurden die Faktoren, die zu Fehldiagnosen führen können, und die aktuellen Richtlinien erörtert. Klicken Sie 

, um die Aufzeichnung anzusehen und die FAQs zu diesem Seminar herunterzuladen.

Vielen Dank, dass Sie uns bei der Serie begleitet haben. Die Folien des Lab Talk können Sie über den unten stehenden Link herunterladen.

Download, Lab Talk Vortrag

Die FAQs zu der KIT D816V Testung sind jetzt zum Download verfügbar

Wenn Sie Fragen zu dieser Serie haben oder mehr über das DXRX-Netzwerk erfahren möchten, wenden Sie sich bitte an help@dxrx.io.  

1. William  Shomali,  Jason  Gotlib;  The  new  tool  “KIT”  in  advanced  systemic  mastocytosis.  Hematology  Am  Soc  Hematol  Educ  Program  2018;  2018  (1):  127–136.

In den vergangenen sechs Monaten hat Diaceutics eine Reihe digitaler Aktivitäten durchgeführt, die sich auf die Bedeutung der Detektion von KIT D816V bei Patienten mit Verdacht auf SM konzentrierten.

on the HER2 testing landscape and the need for 

 to optimize performance in the diagnostic process to 

ensure eligible patients receive targeted therapies. 

This Lab Talk took place on 5th June 2024.

DXRX Lab Talk: A new perspective on HER2 testing. Evolving the lab practices to match clinical advances

This session analyzes the clinical utility of HER2 testing, technical considerations (both pre-analytical and analytical), scoring reproducibility and includes a Q&A session with Prof. Dr Abeer Shaaban MBBCh, MSc, PhD, FRC Path​.

FAQs

 Prof. Dr Abeer Shaaban MBBCh, MSc, PhD, FRCPath​

Prof. Dr Shaaban is a Consultant Pathologist at Queen Elizabeth Hospital Birmingham and Professor of Cancer and Genomic Sciences, University of Birmingham, UK.

As the CRUK Birmingham Centre Pathologist, she supported translational and digital pathology & multiplex immunofluorescence studies

She has led a number of research studies and contributed to breast cancer trials as co-investigator, member of a Trial Management Group and as a central pathology reviewer. Her research interest includes profiling tumour microenvironment, tissue microarrays, predictors of response/resistance to therapies and ethnic differences in cancer.

She was member of the NCRI Breast CSG for two terms and acted as chair of the NCRI Breast CSG Translational Subgroup for 5 years. The subgroup produced several landmark publications including guidance on improving the turnaround of HER2 testing, manufacture and reporting of tissue microarrays and handling of neoadjuvant chemotherapy specimens.

Prof. Dr Shaaban published over 150 peer reviewed papers and contributed a number of book chapters including in the WHO Blue Book for Breast tumours 2019 and the International Collaboration on Cancer Reporting (ICCR)DCIS dataset 2021. She co-edited a textbook of molecular pathology entitled “Molecular pathology for the practising surgical pathologist and cytopathologists”. She lectured on a number of UK and international courses/conferences including San Antonio Breast Cancer Symposium, BDIAP, ESSO, EBBC, Pathological Society of Great Britain and Ireland meetings and other. Prof Shaaban organises an annual multidisciplinary breast pathology update course 

http://birminghambreastpathology.org/bbpuc-2021

Prof. Dr Shaaban led the NCRI Cellular and Molecular Pathology initiative (CM-PATH) Workstream 2 (Clinical Trials). She served as member of the International Committee of the Royal College of Pathologists, member of the Scientific Advisory Board of Breast Cancer Now and is Breast Screening Advisor for Public Health England.

This  event  is  sponsored  by  AstraZeneca.  This  content  is  intended  for  healthcare  professionals  only. Z4-62777. Any use and distribution of the information contained in this document must be assessed and approved in accordance with regional/local approval processes to ensure compliance with applicable local laws, regulations, codes and AZ policies.

This content is organized and funded by AstraZeneca. This content is intended for healthcare professionals only. Z4-62777. DOP: June 2024. 

Download 

The landscape of non-small cell lung cancer (NSCLC) treatment is evolving rapidly. Recent advancements in therapeutic options have reshaped treatment pathways, particularly for metastatic NSCLC. Traditionally dominated by chemotherapy, the current treatment pathway increasingly emphasizes targeted therapies and immunotherapies, offering new hope for improved patient outcomes.NSCLC constitutes a staggering 85% of all lung cancer cases. In the US, biomarker testing plays a pivotal role in tailoring treatments, by assessing genetic mutations and protein expressions, clinicians can select optimal therapies, emphasizing the critical importance of understanding the biomarker landscape in NSCLC. By leveraging the robust capabilities of our DXRX Data Repository, we provide unparalleled insights into this landscape.

Diaceutics’ mission is to ensure that every patient receives the right treatment at the right time to positively benefit their disease outcome. Utilizing multiple integrated pipelines of real-world data on our platform, DXRX - The Diagnostic Network®, we deliver a complete view of the patient journey. Our unique business rules enable detailed patient analysis through a Diagnostic Deductive Pathway (DDP®), providing a granular understanding of each patient's steps along the complex treatment pathway. These insights empower our customers to refine their drug commercialization strategies.

Our analysis tracks the use of these innovative therapies, as well as the rise in the use of specific biomarkers such as PD-L1, EGFR, BRAF, and ALK. The evolving trends in metastatic NSCLC treatment impact the patient journeys of thousands of individuals diagnosed with this challenging disease. Lung cancer remains the leading cause of cancer-related deaths worldwide, and the prognosis for metastatic NSCLC has historically been poor. However, the advent of new treatments is gradually improving these outcomes, offering renewed hope for patients and their families.

Discover more in our metastatic NSCLC Data Fact Sheet. Dive into the data and uncover how Diaceutics’ insights can enhance your drug commercialization strategies and implementation. 

Discover up-to-date Insights on metastatic NSCLC based on real-world data from our DXRX Network

Insights

NTRK positivity and conversion to appropriate personalized treatment.

Catch-up on the series: HER2 Testing in Breast Cancer

KIT D816V Testung bei Systemischer Mastozytose (SM) kompakt dargestellt

A new perspective on HER2 testing – Evolving the lab practices to match clinical advances

Data Fact Sheet: NSCLC

NTRK positivity and conversion to appropriate personalized treatment.

Catch-up on the series: HER2 Testing in Breast Cancer

KIT D816V Testung bei Systemischer Mastozytose (SM) kompakt dargestellt

A new perspective on HER2 testing – Evolving the lab practices to match clinical advances​

Data Fact Sheet: NSCLC

A new perspective on HER2 testing – Evolving the lab practices to match clinical advances